INTRODUCTION
============

In farm animals, up to 45% of conceptuses fail to implant to the uterine endometrium where embryonic mortality occurs most frequently during the first to third week period after conception ([@b21-ajas-26-5-638-5]). During this period, conceptuses of ruminants such as cow and sheep go through blastocyst formation, hatching, migration, elongation, apposition, attachment and limited invasion to the uterine epithelium, and the initiation of placental formation. For these processes, an outer layer of the blastocyst, trophectoderm, goes through extensive cell proliferation as well as differentiation. These changes in the trophectoderm are regulated through numerous gene expressions in a temporal and spatial manner both at the blastocyst and uterus. The regulation of these changes become critical, if a pregnancy is to be established.

Gene expressions in the formation of blastocysts have been extensively studied in mice. As blastocyst development proceeds, the POU transcription factor, OCT4 (Pou5f1), becomes progressively restricted, first to the entire inner cell mass (ICM) and then to the epiblast ([@b20-ajas-26-5-638-5]; [@b18-ajas-26-5-638-5]; [@b22-ajas-26-5-638-5]). Caudal related homeobox 2 transcription factor, CDX2, is involved in the control of cell differentiation into the trophectoderm (TE) and the intestinal epithelium in mice ([@b27-ajas-26-5-638-5]; [@b2-ajas-26-5-638-5]; [@b4-ajas-26-5-638-5]). OCT4 and CDX2 have an inverse relationship in early embryos, and the expression of CDX2 in pre- and early post-implantation embryos is tightly restricted to the TE lineage ([@b2-ajas-26-5-638-5]; [@b19-ajas-26-5-638-5]). Recently, [@b3-ajas-26-5-638-5] demonstrated that *OCT4* transcripts coexist with *CDX2* in the bovine TE and bovine *OCT4* gene transfected into the mouse TE is actively transcribed. These investigators concluded that OCT4 and CDX2 do not coexist in the mouse TE because it implants to the maternal endometrium in a very short time period while in other species including humans, down-regulation of OCT4 is slow, resulting in the expression of both factors in the TE ([@b3-ajas-26-5-638-5]).

Interferon-tau (IFNT), produced by the mononucleate TE of ruminant ungulates during the peri-implantation period ([@b9-ajas-26-5-638-5]; [@b11-ajas-26-5-638-5]; [@b6-ajas-26-5-638-5]), is a major protein that signals the process of maternal recognition of pregnancy ([@b10-ajas-26-5-638-5]; [@b12-ajas-26-5-638-5]; [@b26-ajas-26-5-638-5]; [@b21-ajas-26-5-638-5]). However, a method to effectively control IFNT production and to improve pregnancy rate has not been developed despite the fact that *IFNT* was identified over two decades ago. Using human choriocarcinoma (JEG-3 or JAR) cells, transcription factor AP-1 (official symbol, JUN) and ETS2 binding sites at the distal and proximal promoter regions, respectively, have been shown to be effective in *IFNT*-reporter transactivation ([@b7-ajas-26-5-638-5], [@b8-ajas-26-5-638-5]; [@b29-ajas-26-5-638-5], [@b30-ajas-26-5-638-5]). Additionally, [@b8-ajas-26-5-638-5] found that OCT4 binds to and inhibits the action of ETS2 on bovine *IFNT* in a heterologous over-expression system. These results suggest that the POU domain of OCT4 interacts directly with the central domain of ETS2 to act as a co-repressor. According to [@b8-ajas-26-5-638-5], OCT4 expression subsides long before the initiation of conceptus elongation, when ETS2 begins to activate bovine *IFNT* gene transcription. *In situ* hybridization results suggested that *OCT4* mRNA was restricted to the ICM in d 7 bovine blastocysts ([@b14-ajas-26-5-638-5]; [@b23-ajas-26-5-638-5]). However, further studies revealed that *OCT4* expression remained until d 12 and 13, just prior to conceptus elongation ([@b5-ajas-26-5-638-5]), or even longer period ([@b3-ajas-26-5-638-5]).

We have previously shown that, although the proximal promoter is undoubtedly required, the upstream JUN binding site of the distal enhancer region is also necessary for ovine *IFNT* gene transcription ([@b29-ajas-26-5-638-5]; [@b30-ajas-26-5-638-5]; [@b15-ajas-26-5-638-5]). In addition, the formation of a protein complex between CREBBP, JUN, and ETS2 is required for *IFNT* gene transcription ([@b28-ajas-26-5-638-5]). We recently demonstrated that *IFNT* expression depends not only on the JUN binding site but also on the CDX2 binding site ([@b13-ajas-26-5-638-5]; [@b25-ajas-26-5-638-5]). Moreover, we and others have shown that the CDX2 transcription factor is expressed in ovine and bovine blastocysts during the conceptus elongation period ([@b5-ajas-26-5-638-5]; [@b13-ajas-26-5-638-5]; [@b3-ajas-26-5-638-5]). In fact, the over-expression of CDX2, JUN, and ETS2 in JEG-3 cells was very effective in increasing the degree of ovine *IFNT*-reporter transcription ([@b13-ajas-26-5-638-5]).

The high acetylation and low methylation (euchromatin) status of histone proteins has recently been shown to be required for *IFNT* gene transcription ([@b24-ajas-26-5-638-5]; [@b25-ajas-26-5-638-5]). More importantly, this euchromatin state is maintained through the expression of CDX2 and CREBBP. Although the involvement of OCT4 in the regulation of bovine *IFNT* gene transcription has been demonstrated ([@b8-ajas-26-5-638-5]), the relationship between CDX2, CREBBP, OCT4, and other transcription factors in *IFNT* gene transcription has not been carefully studied. Thus, the coexistence of OCT4 and CDX2 in TE led us to investigate a possible relationship between these and other *IFNT* gene-related transcription factors in sheep.

MATERIALS AND METHODS
=====================

RNA extraction and semi-quantitative RT-PCR
-------------------------------------------

Total RNAs from conceptuses on d 15, 17, and 21 (n = 4 each) were extracted using Isogen Reagent (Nippon Gene, Toyama, Japan) according to the manufacturer's protocol. RNA (1 μg) extracted from each sample was subjected to reverse transcription (RT) into cDNA using oligo(dT) 12 to 18 primers and SuperScript II (Gibco BRL Life Technologies, Rockville, MD, USA) according to the manufacturer's instructions, and the RT products were used as templates for PCR analysis.

Levels of *OCT4* and *CDX2* as well as *CREBBP*, *JUN*, *ETS2* and *IFNT* mRNAs in peri-implantation conceptuses were examined by PCR using specific primers ([Table 1](#t1-ajas-26-5-638-5){ref-type="table"}). The PCR mixture consisted of 1 μl of RT product, 1 μl of 10×PCR buffer, 0.4 μl each of forward and reverse primers (10 pM), 0.2 μl of dNTP mixture (10 mM), 0.3 μl of MgCl~2~ (50 mM), 6.6 μl of ddH~2~O, and 0.1 μl of Taq DNA polymerase (5 U/μl; Invitrogen, Carlsbad, CA, USA). PCR was performed under the following conditions: 94°C for 5 min, followed by 30 cycles of 94°C for 1 min, 57°C for 1 min, and 72°C for 1 min. The PCR product was analyzed by electrophoresis on a 1% agarose gel stained with ethidium bromide. The cDNA fragment was extracted from the agarose gel using the QIAquick Gel Extraction Kit (Qiagen, Tokyo, Japan) and then cloned into pGEM-T Easy Vector (Promega, Madison, WI, USA). Nucleotide sequences were determined by DNA sequencing (ABI-PRISM, Foster City, CA, USA). *ACTB* mRNA was used as an internal control ([@b24-ajas-26-5-638-5]).

Plasmid constructions
---------------------

The upstream region (between −654 and +51 bp) of ovine *IFNT* gene (IFNτ-o10; [@b17-ajas-26-5-638-5]; GenBank accession number: M88773) and its transcription factor binding-site mutants was amplified by PCR using specific primers ([@b29-ajas-26-5-638-5]; [@b15-ajas-26-5-638-5]). The PCR product was inserted into the pGL3-Basic Vector (Promega), which contained a firefly luciferase gene. All expression vectors, pSG5 (Promega)-based constructs, were driven by the SV40 promoter/enhancer. The plasmid constructs were all confirmed to contain the desired nucleotide sequences by dideoxy sequencing.

Cell culture and transient transfection
---------------------------------------

Human choriocarcinoma JEG-3 cells (HTB36; American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, MO) supplemented with 10% (v/v) fetal bovine serum (FBS; Sigma-Aldrich), 40 U/ml penicillin, and 40 μg/ml streptomycin under 5% CO~2~ at 37° C. JEG-3 cells were re-plated onto 24-well plastic culture plates for 24 h and allowed to reach 60% to 70% confluence. Cells were transiently transfected with reporter constructs and/or expression plasmids using 3 μl of TransFast (cationic lipids; Promega) according to the manufacturer's protocol. To each well of the 24-well plates, 1 μg of total plasmid DNA was added in duplicate (12 treatments/plate, n = 4) in 200 μl DMEM. After 1 h incubation at 37°C, 1 ml of DMEM containing 10% FBS was added to each well, and the transfected cells were cultured for 48 h. To normalize transfection efficiency, the pRL-*TK* vector (containing the herpes simplex virus thymidine kinase promoter and the *Renilla* luciferase gene; Promega), along with each pGL3 vector, was transfected into JEG-3 cells. The ratio of pGL3 to pRL-*TK* was optimized at 160:1 ([@b13-ajas-26-5-638-5]).

For cotransfection experiments, pGL3 (800 ng), expression vector (140 ng), and pRL-*TK* (5 ng) plasmids were added to the medium. For cotransfection of 2 or more types of expression vectors, the ratio of the plasmids was 1:1:1 (35:35:35 ng). Throughout cotransfection studies, the total amounts of expression plasmids were kept constant by using the pSG5-based empty plasmid.

For the 0/24 h transfection experiment, the initial transfection at 0 h was performed as mentioned above. After 24 h of incubation, the medium containing 10% FBS was replaced with medium without FBS, and transfection of expression plasmid(s) was performed in the same manner. These cells were incubated for a further 24 h.

For immunoprecipitation studies, 24 μg of expression plasmids was transfected into JEG-3 cells, which had been cultured to 70% to 80% confluence. Two kinds of plasmids (12 μg each) or 4 kinds of plasmids (6 μg each) were transfected into JEG-3 cells by the aforementioned method.

Luciferase reporter assay
-------------------------

Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. At 48 h of incubation following the plasmid transfection, JEG-3 cells were washed with phosphate-buffered saline (PBS) and lysed with Passive Lysis Buffer (Promega). A total of 20 μl each of the various lysates was placed into a 96-well plate and luciferase activity was measured using a luminometer (PerkinElmer, Foster City, CA, USA). The luciferase activity resulting from the various ovine *IFNT*-reporter constructs was normalized by dividing the luminescence of firefly luciferase by that of *Renilla* luciferase ([@b13-ajas-26-5-638-5]). Luciferase activities were expressed as fold activation relative to an appropriate control, the ovine *IFNT*-reporter construct without expression plasmids, within the experiment.

Nuclear protein extraction, western blotting, and co-immunoprecipitation analyses
---------------------------------------------------------------------------------

Nuclear proteins were extracted from JEG-3 cells (5×10^6^ cells) transfected with expression constructs according to the protocol described previously ([@b15-ajas-26-5-638-5]; [@b13-ajas-26-5-638-5]). Concentrations of nuclear extracts were determined by using the Bio-Rad Protein Assay Dye Reagent Concentrate (Bio-Rad Laboratories, Hercules, CA, USA). A total of 10 μg of nuclear extracts was loaded onto each lane and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins in the gel were transferred onto polyvinylidene difluoride (PVDF) membrane (pore size, 0.45 μm; Millipore, Bedford, MA, USA) by electro-blotting ([@b15-ajas-26-5-638-5]) and then treated with rabbit polyclonal antibody against the DNA-binding domain of mouse JUN (D, 0.04 μg/ml; Santa Cruz Biotechnology, Santa Cruz, CA, USA), the C-terminus of human ETS2 (C-20, 0.04 μg/ml; Santa Cruz Biotechnology), the N-terminus of human CDX2 (ab22586, 0.04 μg/ml; Abcam, Cambridge, UK), the N-terminus of human OCT4 (N-19, 0.04 μg/ml; Santa Cruz Biotechnology), or the C-terminus of human CREBBP (C-1, 0.04 μg/ml; Santa Cruz Biotechnology). Normal rabbit IgG (Sigma-Aldrich) was used as a negative control. The membrane was treated with the secondary antibody, donkey anti-rabbit IgG conjugated with horseradish peroxidase (Amersham Pharmacia Biotech, Buckinghamshire, UK), and then detected by using an ECL western blotting detection system (Amersham Pharmacia Biotech).

For immunoprecipitation studies, mouse monoclonal antibody against human CREBBP (C-1, 20 μg; Santa Cruz Biotechnology) was incubated with 10 μl of protein A Sepharose beads (Amersham Pharmacia) at 4°C for 4 h ([@b13-ajas-26-5-638-5]; [@b24-ajas-26-5-638-5]; [@b25-ajas-26-5-638-5]). Anti-CREBBP antibody pretreated with blocking peptide was used as a negative control. The beads were pelleted and washed 3 times in PBS containing 0.1% Tween-20 (Wako Chemical Industries, Ltd., Osaka, Japan). The pellets were then mixed with 40 μg of nuclear proteins prepared from JEG-3 cells and incubated at 4°C overnight. The mixture was pelleted and washed 3 times in PBS containing 1% Tween-20, and the final pellets were suspended and separated by 10% SDS-PAGE. The immunoprecipitates were assayed by western blotting using rabbit polyclonal antibody against JUN (D, 0.04 μg/ml) or ETS2 (C-20, 0.04 μg/ml) (Santa Cruz Biotechnology). Normal rabbit IgG (Sigma-Aldrich) was used as a negative control.

Statistical analysis
--------------------

The results of luciferase assays were expressed as the means±SEM. Differences in fold activation (luciferase activity) were examined by ANOVA, followed by Fisher's LSD multiple comparison tests.

RESULT
======

Semi-quantitative analysis of transcription factor mRNAs in peri-attachment ovine conceptuses
---------------------------------------------------------------------------------------------

The levels of *CDX2* mRNA were highest on d 17, with expression patterns preceding those of *IFNT* mRNA. Strong expression of *OCT4* mRNA was detected on d 15, 17, and 21 of gestation. Similar levels of transcription factor *CREBBP*, *JUN*, *ETS2* mRNAs were found this time period whereas *IFNT* mRNA declined ([Figure 1A](#f1-ajas-26-5-638-5){ref-type="fig"}). The efficacy of all pSG5-based expression vectors was examined by transient transfection into JEG-3 cells, from which the nuclear proteins (cell lysates) were isolated and subjected to western blot analysis. All expression constructs exhibited proteins of the expected sizes ([Figure 1B](#f1-ajas-26-5-638-5){ref-type="fig"}).

Effects of JUN, CDX2, ETS2 and/or OCT4 on *IFNT* gene transcription
-------------------------------------------------------------------

Similar to our previous study ([@b13-ajas-26-5-638-5]), the luciferase activity of the -654-*IFNT*-Luc transfected with *Jun*, *Ets2* and *Cdx2* expression plasmids was approximately 12 times that of the -654-*IFNT*-Luc plasmid alone ([Figure 2](#f2-ajas-26-5-638-5){ref-type="fig"}). To investigate whether OCT4 affected ovine *IFNT* gene transcription, the -654-*IFNT*-Luc construct was transiently transfected into JEG-3 cells with *Oct4* in combination with *Jun*, *Ets2* and/or *Cdx2* expression plasmids, and luciferase activities were measured. OCT4 inhibited transcription of -654-*IFNT*-Luc when either *Jun*, *Ets2*, *Cdx2*, or *Jun/Ets2* together with the reporter construct was transfected into JEG-3 cells. However, OCT4 did not suppress the level of the -654-*IFNT*-Luc transcription when *Cdx2* was cotransfected into JEG-3 cells along with *Jun*, *Ets2*, or *Jun/Ets2*.

Effect of JUN, CDX2, and/or ETS2 binding sites on *IFNT* gene transcription
---------------------------------------------------------------------------

To investigate whether preventing the binding of JUN, ETS2, and/or CDX2 resulted in decreased *IFNT* gene transcription, the upstream binding sites of the -654-*IFNT*-Luc reporter construct were mutated and transfected into JEG-3 cells along with the 3 transcription factors. As shown in [Figure 3](#f3-ajas-26-5-638-5){ref-type="fig"}, mutation of any of the binding sites resulted in reduced luciferase activities. These results indicate that JUN, ETS2, and CDX2 transcription factors may form a complex (or complexes) required for ovine *IFNT* gene transcription, and that each factor requires a specific binding site on the upstream region of the ovine *IFNT* gene. In addition, cotransfection of the *Oct4* expression plasmid along with *Jun*, *Ets2* and *Cdx2* did not change the level of luciferase activity, which had already been reduced due to mutation of the binding sites.

Effect of the timing of OCT4 expression on *IFNT* gene transcription
--------------------------------------------------------------------

Since OCT4 over-expression concurrent with transfection of *Jun*, *Ets2*, and *Cdx2* did not inhibit activity on -654-*IFNT*-Luc transcription, the effect of the timing of transcription factor expression on -654-*IFNT*-Luc transcription was examined. Experiments were performed using various combinations of transcription factor expression plasmids, which were transfected into JEG-3 cells at 0 or 24 h after the initiation of the experiment. The maximum inhibitory effect of OCT4 on ovine *IFNT* gene transcription was found when *Oct4* alone was transfected prior to the transfection of any other transcription factor expression plasmids (0 h; [Figure 4](#f4-ajas-26-5-638-5){ref-type="fig"}). Transfection of *Oct4* at 24 h did not inhibit *IFNT*-Luc transcription. The results of the 0/24 h experiment were consistent with our hypothesis that substantial *IFNT* gene transcription requires the formation of a transcription factor complex.

CREBBP inhibition reduces *IFNT* gene transcription
---------------------------------------------------

To evaluate the role of CREBBP on *IFNT* transcription, JEG-3 cells were cotransfected with the -654-*IFNT*-Luc construct along with *Jun*, *Ets2*, and/or *Cdx2* expression plasmids, either with or without *Oct4* or a CREBBP inhibitor, 12S E1A. No additional increase in ovine *IFNT* gene transcription was observed when *Crebbp* was transfected along with *Jun*, *Ets2* and/or *Cdx2* ([Figure 5](#f5-ajas-26-5-638-5){ref-type="fig"}). However, co-transfection of 12S E1A reduced the level of ovine *IFNT* gene transcription even in the presence of CDX2, and the level of luciferase activity reduction was greater than that resulting from *Oct4* cotransfection.

Association of JUN and ETS2 with CREBBP
---------------------------------------

To determine whether either of these transcription factors directly interact with CREBBP, thereby resulting in changes in ovine *IFNT* gene transcription, co-immunoprecipitation studies were carried out. Targeted transcription factors were co-transfected into JEG-3 cells, of which optimum expression was predetermined for each expression plasmid. The co-immunoprecipitation study ([Figure 6](#f6-ajas-26-5-638-5){ref-type="fig"}) showed that JUN and ETS2 bound to CREBBP, and binding between OCT4 and ETS2 was also demonstrated.

DISCUSSION
==========

It was previously thought that OCT4 expression subsides long before the elongation of bovine conceptuses begins ([@b8-ajas-26-5-638-5]). However, recent studies have shown that OCT4 expression persists much longer in ruminant conceptuses ([@b5-ajas-26-5-638-5]; [@b3-ajas-26-5-638-5]). This study represents the first to examine direct interactions between OCT4, CDX2, and CREBBP within the context of *IFNT* transcriptional regulation. Our data showed that cotransfection of *Cdx2* with *Jun* and *Ets2* into JEG-3 cells resulted in the highest ovine *IFNT* gene transcription, which is in agreement with our previous study ([@b13-ajas-26-5-638-5]). Importantly, OCT4 exhibited inhibitory effects on ovine *IFNT* gene transcription only when *Oct4* was transfected into JEG-3 cells prior to the other expression plasmids. These data imply that OCT4 binding to ETS2 ([@b8-ajas-26-5-638-5]) reduces the availability of ETS2 to form the transcription factor complex, JUN-CREBBP-ETS2, which is required for active *IFNT* transcription ([@b28-ajas-26-5-638-5]; [@b13-ajas-26-5-638-5]). Since the DNA-binding domain of ETS2 is located close to the region, to which OCT4 may bind ([@b8-ajas-26-5-638-5]), the OCT4-ETS2 complex may not be able to bind to the upstream region of the ovine IFNT gene. As CDX2 expression increases, CDX2 binds to residual OCT4 ([@b19-ajas-26-5-638-5]), allowing binding of ETS2 to the JUN-CREBBP-ETS2 complex and activation of ovine *IFNT* gene transcription.

The importance of JUN-CREBBP-ETS2 complex formation for ovine *IFNT* gene transcription ([@b28-ajas-26-5-638-5]) was further evaluated by using a CREBBP inhibitor, 12S E1A. The binding of 12S E1A to CREBBP prevents CREBBP from forming JUN-CREBBP and/or ETS2-CREBBP complexes ([@b1-ajas-26-5-638-5]). In this study, cotransfection of *Crebbp* with *Jun*, *Ets2* and *Cdx2* did not further increase the level of ovine *IFNT* gene transcription. However, the transfection of 12S E1A reduced the level of ovine *IFNT* gene transcription by a greater extent than did *Oct4* transfection. These observations support our hypothesis that disruption of the JUN-CREBBP-ETS2 complex formation results in inactivation of ovine *IFNT* gene transcription.

The presence of *OCT4* mRNA in bovine and ovine trophoblasts detected in the present study and by others ([@b14-ajas-26-5-638-5]; [@b5-ajas-26-5-638-5]; [@b3-ajas-26-5-638-5]; [@b23-ajas-26-5-638-5]) contrasts with data from mouse trophoblasts, in which OCT4 expression is restricted to the ICM ([@b19-ajas-26-5-638-5]). [@b3-ajas-26-5-638-5] showed that the upstream conserved region 4 (CR4) of *OCT4* genes differs between bovine and murine species, and that bovine CR4 is effective for OCT4 expression in mouse TE. Unlike murine blastocysts, ruminant conceptuses go through extensive trophoblast elongation prior to conceptus attachment to the uterine endometrium ([@b16-ajas-26-5-638-5]). It has been suggested that there may be 2 types of trophoblast cell populations in the elongating blastocyst: terminally differentiated and less differentiated. We suspect that the terminally differentiated trophoblast cells produce IFNT, whereas less differentiated cell populations proliferate during the pre-attachment period.

CDX2 functions as a transcription factor that is required for *IFNT* transcription ([@b13-ajas-26-5-638-5]; [@b24-ajas-26-5-638-5]). In addition, CDX2 maintains the euchromatin state for *IFNT* transcription ([@b25-ajas-26-5-638-5]). CDX2 expression declines as conceptus attachment to the uterine epithelium proceeds. Thus, it is possible that reduced expression of CDX2 allows ETS2 to become available for JUN-CREBBP-ETS2 complex formation, while the euchromatin state maintained by CDX2 allows the complex to have full access to the upstream region of *IFNT* gene. Transcription factors and epigenetic regulation allow the TE to produce substantial amounts of IFNT during the conceptus elongation period.

Based on these observations, we propose the following molecular mechanism for ovine *IFNT* gene transcription ([Figure 7](#f7-ajas-26-5-638-5){ref-type="fig"}). When OCT4 expression exceeds that of CDX2 expression, OCT4 binds to ETS2, resulting in minimal formation of the transcription factor complex, JUN-CREBBP-ETS2. Increasing CDX2 expression, along with decreased levels of OCT4 protein, allows CDX2 to bind to residual OCT4, freeing up more ETS2 for formation of the JUN-CREBBP-ETS2 complex. This complex formation and the appropriate binding of these and other transcription factors to the upstream region of the ovine *IFNT* gene results in a high level of ovine *IFNT* gene transcription during the pre-attachment period, when the region is maintained in the euchromatin state.
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![Semi-quantitative RT-PCR showing the presence of transcription factor mRNAs in the ovine conceptuses and western blots showing proteins produced from expression vectors. *CDX2* mRNA was found on days 15 and 17, while *OCT4* mRNA was detected on days 15, 17, and 21 of gestation. During the same period, levels of *CREBBP*, *JUN* and *ETS2* in ovine conceptuses were similar whereas *IFNT* mRNA declined (Figure 1A). The efficacy of all pSG5-based expression vectors was examined via transient transfection into JEG-3 cells, from which nuclear proteins (cell lysates) were isolated and subjected to western blot analysis. All expression constructs exhibited proteins of the expected sizes (Figure 1B). In both cases, one of four replicates is shown.](ajas-26-5-638-5f1){#f1-ajas-26-5-638-5}

![The effect of transfection of *Jun*, *Cdx2* and *Ets2* along with *Oct4* on *IFNT* gene transcription. The luciferase activity of -654-*IFNT*-Luc transfected with *Jun*, *Ets2* and *Cx2* expression plasmids was approximately 12 times that of the -654-*IFNT*-Luc plasmid alone. OCT4 inhibited -654-*IFNT*-Luc transcription when either *Jun*, *Ets2*, *Cdx2*, or *Jun/Ets2*, together with the reporter construct, was transfected into JEG-3 cells. However, OCT4 did not suppress the level of -654-*IFNT*-Luc transcription when *Cdx2* was cotransfected with *Ets2*, *Jun* or *Ets2/Jun* into JEG-3 cells.](ajas-26-5-638-5f2){#f2-ajas-26-5-638-5}

![Examination of the effect of JUN, CDX2, and/or ETS2 binding sites on *IFNT* gene transcription. Cotransfection of the transcription factor binding site-mutated -654-*IFNT*-Luc construct with *Jun*, *Ets2* and *Cdx2* reduced luciferase activities. However, cotransfection of the *Oct4* expression plasmid along with *Jun*, *Ets2* and *Cdx2* did not change the degree of luciferase activity, which had already been reduced due to mutation of the transcription factor binding sites.](ajas-26-5-638-5f3){#f3-ajas-26-5-638-5}

![Effects of various combinations of transcription factors that were transfected into JEG-3 cells at 0 or 24 h after initiation of the experiment. The maximum inhibitory effect of OCT4 on ovine *IFNT* gene transcription was found when *Oct4* alone was transfected prior to any other transcription factor expression plasmids. From the 0/24 h experiments, the initial expression and/or complex formation between the transcription factors appeared to determine the subsequent degree of ovine *IFNT* gene transcription.](ajas-26-5-638-5f4){#f4-ajas-26-5-638-5}

![Effect of CREBBP on ovine *IFNT* gene transcription. No additional increase in ovine *IFNT* gene transcription was observed when *Crebbp* was cotransfected with *Jun*, *Ets2* and/or *Cdx2*. However, cotransfection of 12S E1A reduced the level of ovine *IFNT* gene transcription even in the presence of CDX2, and the level of luciferase activity reduction appeared to be more than that produced by *Oct4* cotransfection.](ajas-26-5-638-5f5){#f5-ajas-26-5-638-5}

![Determination of the relationship between JUN/ETS2 and/or CREBBP using co-immunoprecipitation. A. *Jun* and *Crebbp* expression plasmids were transfected into JEG-3 cells, from which the nuclear proteins were extracted. These extracts were subjected to immunoprecipitation with anti-CREBBP antibody, followed by western blot analysis with anti-JUN antibody. B. *Ets2* and *Crebbp* expression constructs were transfected into JEG-3 cells, from which nuclear proteins were subjected to immunoprecipitation with anti-CREBBP antibody, followed by western blot analysis with anti-ETS2 antibody. C. Immunoprecipitation and western blot analyses were performed using nuclear extracts isolated from JEG-3 cells, into which *Jun*, *Ets2*, *Cdx2*, *Crebbp*, and *Oct4* expression constructs were transfected. D. *Ets2* and *Oct4* expression plasmids were transfected into JEG-3 cells, from which nuclear proteins were subjected to immunoprecipitation with anti-OCT4 antibody, followed by western blot analysis with anti-ETS2 antibody. Binding between OCT4 and ETS2 was also demonstrated.](ajas-26-5-638-5f6){#f6-ajas-26-5-638-5}

![Model showing the molecular mechanism of activation of ovine *IFNT* gene transcription. When OCT4 expression predominates in the ovine blastocyst, OCT4 binding to ETS2 ([@b8-ajas-26-5-638-5]) may limit the formation of the JUN-CREBBP-ETS2 complex ([@b28-ajas-26-5-638-5]). As CDX2 expression increases and OCT4 expression subsides, the CDX2 to OCT4 ratio increases ([@b3-ajas-26-5-638-5]), which loosens the chromatin structure (euchromatin state; [@b25-ajas-26-5-638-5]). These CDX2 proteins bind to residual OCT4 ([@b19-ajas-26-5-638-5]), allowing ETS2 to form the JUN-CREBBP-ETS2 complex. The appropriate assembly of transcription factors at the euchromatin state results in maximum transcription of the ovine *IFNT* gene during the period of conceptus elongation.](ajas-26-5-638-5f7){#f7-ajas-26-5-638-5}

###### 

Oligonucleotide primer sequences used for RT-PCR

  Gene                       GenBank Accession   Primers (5′-3′) (Forward (F) and Reverse (R))   Length (bp)
  -------------------------- ------------------- ----------------------------------------------- -------------
  *IFNT*                     M60903              F: cagaaaagactttggtcttcc                        166
  R: agtgcagagctgctccaggag                                                                       
  *OCT4*                     DQ126156            F: gagaggcaacctggagag                           337
  R:cagagcggtgacagacac                                                                           
  *CDX2*                     XM\_ 871005         F: tatcaccatccggaggaaag                         414
  R: gagggctaggtcagctggta                                                                        
  *ETS2*                     DQ126148            F: gggcctatccagctgtgg                           227
  R: ttccctgacgtcttgtggat                                                                        
  *CREBBP*                   XM_581740           F: caaggagctgccctactttg                         226
  R: tttttcttggcgttcttgct                                                                        
  AP-1(*JUN*)                AF069514            F: ggaaacgaccttctatgacg                         160
  R: ggagttcttggcccggaggt                                                                        
  *ACTB*                     BC102948            F: ctcttccagccttccttcct                         178
  R: gggcagtgatctctttctgc                                                                        
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